Entrada Therapeutics(TRDA) - 2024 Q2 - Quarterly Results

Entrada Therapeutics Reports Second Quarter 2024 Financial Results – Generated positive data from the Phase 1 clinical trial of ENTR-601-44 for DMD, including dose-dependent plasma and muscle concentration, and exon skipping – – Planning underway for separate global Phase 2 clinical trials for ENTR-601-44 and ENTR-601-45 with regulatory filings anticipated in Q4 2024 – – Completed $100 million registered direct offering led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Hende ...